Health and bio · United Kingdom · founded 2021
Isomorphic Labs valuation and IPO status
Isomorphic Labs's latest valuation figure, $50B (17 Nov 2026), comes from reported funding talks, not a priced transaction. IPO status: private.
Source tier: ReportedSource: The Next Web (citing Bloomberg)
Information only, not investment advice. Figures are from public sources; tiers show how solid each one is.
About Isomorphic Labs
Alphabet's AI drug-discovery company, spun out of DeepMind and run by Demis Hassabis; no drug is in human trials yet.
Closed a $5B Series C on 17 Nov 2026 led by Greenoaks and Sequoia (company announcement) without disclosing the valuation; Bloomberg reported it was raising at about $50B.
Key investors
Alphabet, Greenoaks, Sequoia Capital, Andreessen Horowitz, Thrive Capital, GV, CapitalG, MGX, Temasek, UK Sovereign AI Fund.
Isomorphic Labs: quick answers
How much is Isomorphic Labs worth?
Isomorphic Labs has no disclosed priced valuation. Reported funding talks put it at $50B (17 Nov 2026), according to The Next Web (citing Bloomberg), so it is not ranked in our tracker. We label it reported.
Is Isomorphic Labs going public?
Status: private.
Who invests in Isomorphic Labs?
Named investors include Alphabet, Greenoaks, Sequoia Capital, Andreessen Horowitz, Thrive Capital, GV, CapitalG, MGX, Temasek, UK Sovereign AI Fund.
Sources
- The Next Web (citing Bloomberg). thenextweb.com, Source tier: Reported
- Bloomberg. bloomberg.com, Source tier: Reported